List of Excipients in Branded Drug HYDROXYZINE HCL

Generic Drugs Containing HYDROXYZINE HCL

Company	Ingredient	NDC	Excipient
STI Pharma LLC	hydroxyzine hcl	54879-006	ALCOHOL
STI Pharma LLC	hydroxyzine hcl	54879-006	ANHYDROUS CITRIC ACID
STI Pharma LLC	hydroxyzine hcl	54879-006	METHYLPARABEN
STI Pharma LLC	hydroxyzine hcl	54879-006	PEPPERMINT OIL
STI Pharma LLC	hydroxyzine hcl	54879-006	PROPYLENE GLYCOL
STI Pharma LLC	hydroxyzine hcl	54879-006	SODIUM CITRATE
STI Pharma LLC	hydroxyzine hcl	54879-006	SPEARMINT OIL

What are the Most Frequently-Used Excipients in HYDROXYZINE HCL?

# Of NDCs	Excipient
1	ALCOHOL
1	ANHYDROUS CITRIC ACID
2	ANHYDROUS LACTOSE
3	CELLULOSE, MICROCRYSTALLINE
2	CROSPOVIDONE
1	HYPROMELLOSE 2910
2	HYPROMELLOSES

Hydroxyzine HCl Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Hydroxyzine hydrochloride is a mature, low-cost generic antihistamine and anxiolytic with limited compound-patent value. Commercial opportunities depend on formulation execution: palatable oral liquids, rapidly disintegrating tablets, unit-dose packaging, preservative-controlled products, and differentiated dosing formats. The strongest opportunities are in patient convenience, pediatric and geriatric administration, pharmacy supply reliability, and lower-risk excipient systems rather than exclusivity.

What is the regulatory and commercial status of hydroxyzine HCl?

Hydroxyzine hydrochloride is an FDA-approved first-generation antihistamine used for pruritus, anxiety, and preoperative sedation. It is marketed primarily as generic tablets, capsules, oral solutions, syrups, and in some markets injectable products. Hydroxyzine pamoate is a separate salt and should not be treated as an interchangeable excipient or formulation equivalent to hydroxyzine HCl.

Attribute	Hydroxyzine HCl
Active ingredient	Hydroxyzine hydrochloride
Therapeutic class	First-generation H1 antihistamine; anxiolytic
Common dosage forms	Tablets, capsules, oral solution, syrup
Typical commercial status	Generic, multisource
FDA pathway for new products	ANDA for equivalent products; 505(b)(2) possible for materially differentiated dosage forms
Orange Book relevance	Product-specific patent and exclusivity review is required by application number
Compound-patent position	Legacy molecule; no commercially meaningful new-molecule exclusivity expected
Primary formulation risks	Taste, sedation-related dosing errors, precipitation, microbial control, moisture, dose uniformity
Main market constraint	Low unit price and extensive generic competition

FDA labeling identifies hydroxyzine HCl for symptomatic management of anxiety, pruritus, and preoperative sedation. Labels also contain central nervous system depression warnings and contraindications or precautions relating to QT prolongation and cardiac arrhythmias.[1,2]

Hydroxyzine HCl has no biosimilar pathway. It is a small-molecule generic drug. Competitive entry is therefore governed by ANDA requirements, product quality, supply reliability, manufacturing scale, and any formulation-specific intellectual property.

What excipients are used in hydroxyzine HCl products?

Hydroxyzine HCl formulations typically use conventional oral solid and liquid excipient systems. Exact compositions vary by manufacturer and dosage form.

Tablet and capsule excipients

Relevant excipient classes include:

Function	Candidate excipient classes	Commercial purpose
Diluent	Lactose, microcrystalline cellulose, dibasic calcium phosphate, mannitol	Tablet mass and manufacturability
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Granule strength and tablet robustness
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Rapid tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and process control
Glidant	Colloidal silicon dioxide, talc	Powder flow
Film former	Hypromellose, polyvinyl alcohol	Appearance, handling, swallowability
Plasticizer	Polyethylene glycol, triethyl citrate	Film flexibility
Opacifier or colorant	Titanium dioxide, iron oxides, permitted colorants	Product identification and light control

Hydroxyzine HCl is water-soluble, so dissolution is usually less difficult than for poorly soluble antihistamines. The formulation target is often rapid disintegration, adequate content uniformity, low friability, and acceptable taste rather than aggressive solubility enhancement.

Direct compression can reduce manufacturing steps and cost when powder flow and content uniformity are controlled. Wet granulation can improve blend uniformity and tablet strength but increases process complexity and exposure to moisture. A dry-granulation platform may be appropriate where moisture sensitivity, compression behavior, or scale-up economics make direct compression unsuitable.

Oral liquid excipients

Hydroxyzine HCl oral liquids require a different risk profile:

• Purified water as the vehicle.
• Glycerin, sorbitol, or propylene glycol for viscosity and mouthfeel.
• Sweeteners such as sucrose, sorbitol, sucralose, or saccharin sodium.
• Flavor systems to reduce bitterness and medicinal aftertaste.
• Buffer systems to control pH.
• Chelating agents such as disodium EDTA where justified.
• Preservatives such as sodium benzoate or parabens, depending on pH, packaging, and microbial challenge results.
• Suspending or thickening agents where the product is a suspension rather than a true solution.

The preferred approach for hydroxyzine HCl is generally a clear solution when concentration, taste, chemical stability, and preservative performance permit. A suspension can increase formulation flexibility but creates additional requirements for redispersibility, dose uniformity, sedimentation control, and shake-well labeling.

Which excipient strategy is strongest for hydroxyzine HCl tablets?

The strongest baseline strategy is a low-cost immediate-release tablet using a conventional filler-binder-disintegrant system with rapid disintegration and minimal excipient count.

A practical development sequence is:

1. Establish hydroxyzine HCl assay and content uniformity across the intended dose range.
2. Screen direct compression against dry or wet granulation.
3. Optimize disintegration without creating excessive friability.
4. Control lubricant concentration and blending time because over-lubrication can slow wetting and dissolution.
5. Evaluate moisture uptake, tablet hardness, friability, and dissolution after accelerated stability.
6. Use film coating only when it improves identification, swallowability, taste masking, or handling.

A low-excipient tablet can provide a commercial advantage for patients with excipient sensitivities and for manufacturers seeking simpler supply chains. However, "excipient-free" positioning is not realistic because tablets require functional processing materials.

Potential differentiation includes:

• Lactose-free tablets for patients avoiding lactose.
• Lower-sodium formulations where sodium-containing excipients are used.
• Dye-free tablets.
• Gluten-free manufacturing claims supported by controls.
• Smaller tablets for pediatric or geriatric patients.
• Scored tablets where dose splitting is validated.
• High-contrast imprinting and packaging for medication-error reduction.

These claims require product-specific substantiation and regulatory review. They do not independently create market exclusivity.

What excipient strategy is strongest for hydroxyzine HCl oral liquids?

Oral liquid formulation offers the clearest product-development opportunity because hydroxyzine is commonly used in populations that may have difficulty swallowing tablets, including children and older adults.

Palatability strategy

Hydroxyzine has a bitter, medicinal taste. Taste masking should be treated as a primary development objective rather than a packaging issue. Options include:

• High-intensity sweetener systems.
• Flavor combinations using fruit, vanilla, citrus, or berry profiles.
• Viscosity adjustment to reduce immediate oral exposure.
• pH adjustment where compatible with stability and tolerability.
• Ion-pairing or resin-complex approaches if a simple flavor system is inadequate.
• Unit-dose oral syringes that reduce volumetric error and shorten mouth contact.

Hydroxyzine HCl is soluble, which can simplify liquid development. A fully dissolved product can improve dose uniformity compared with a suspension, but the developer must verify chemical stability, preservative effectiveness, pH drift, and container compatibility.

Preservative strategy

Preservative selection should be driven by the final pH, water activity, packaging configuration, microbial challenge testing, and multidose in-use period. Sodium benzoate is common in acidic oral liquids, but its suitability depends on the finished formulation. Parabens can provide broad preservation but may create labeling, patient-acceptability, or compatibility considerations.

A preservative-free opportunity may exist in unit-dose packaging, but the economics must support higher packaging costs. Unit-dose cups, sachets, or prefilled oral syringes can reduce contamination risk and improve administration accuracy.

Sugar-free strategy

A sugar-free hydroxyzine HCl solution can target diabetes-conscious consumers, institutional formularies, and pediatric markets. Polyols such as sorbitol and glycerin can improve mouthfeel, but excessive polyol content may cause gastrointestinal intolerance. A combined sweetener and flavor system is usually preferable to relying on a single sweetener.

What differentiated hydroxyzine HCl dosage forms have commercial potential?

Pediatric oral solution

Pediatric oral solution is the most direct commercial opportunity. The product should prioritize:

• Accurate dosing with an oral syringe.
• Low bitterness.
• Sugar-free and dye-free options.
• Clear concentration labeling.
• Child-resistant packaging with an accessible measuring device.
• Stability across normal storage conditions.
• Low fill-volume variability.

Hydroxyzine dosing can be clinically sensitive because the drug causes sedation. Concentration selection must reduce the risk of tenfold dosing errors. A high-concentration product may lower administration volume but increase accidental-overdose risk. A lower concentration improves dose measurement at small doses but raises shipping and packaging costs.

Orally disintegrating tablet

An orally disintegrating tablet could address swallowing difficulty and improve administration without water. The main technical barriers are bitterness, tablet friability, moisture sensitivity, and packaging cost.

Candidate excipient platforms include mannitol for mouthfeel, crospovidone or croscarmellose sodium for rapid disintegration, and taste-masking systems compatible with direct compression. Aluminum-aluminum blister packaging may be required if the formulation is moisture-sensitive, which can reduce the cost advantage of a conventional bottle.

Chewable tablet

A chewable tablet can target pediatric and patient-convenience segments. It requires stronger taste masking than a swallowed tablet and must meet chewable-tablet performance expectations for hardness, friability, dose uniformity, and mouthfeel.

Oral film

A hydroxyzine HCl oral film would provide a differentiated delivery format, but it faces challenges from dose loading, content uniformity over thin films, bitterness, film drying, packaging moisture control, and manufacturing scale. It may be more commercially defensible than a conventional liquid if the product solves a specific administration problem.

Unit-dose institutional product

Hospitals, long-term-care facilities, emergency departments, and behavioral-health settings may value unit-dose packaging. The opportunity is operational rather than pharmacological:

• Lower medication-preparation time.
• Reduced dose-measurement errors.
• Easier inventory control.
• Improved traceability.
• Less multidose-bottle contamination.

What patents protect hydroxyzine HCl formulations?

Hydroxyzine HCl itself is an old active ingredient with no expected remaining composition-of-matter exclusivity in major markets. Conventional tablet and oral-solution formulations are also unlikely to have meaningful broad patent protection.

IP category	Expected position
Composition-of-matter patent	Expired or commercially irrelevant
Conventional tablet formulation	Generally vulnerable to generic competition
Conventional oral solution	Limited patent differentiation
Taste-masked dosage form	Possible formulation or process patents
Orally disintegrating tablet	Possible dosage-form patents, subject to claim scope
Oral film	Possible formulation, film-process, or packaging patents
Device-enabled dosing	Possible combination or device claims
Manufacturing process	Possible process patents if technically specific
Method of use	Potentially narrow and vulnerable, depending on jurisdiction

Any new patent strategy would need to claim a measurable technical advantage, such as improved stability, reduced bitterness, defined dissolution performance, reduced degradation, or a specific manufacturing process. Broad claims covering hydroxyzine HCl plus ordinary excipients would face substantial validity and obviousness risk.

A formulation patent may not prevent all generic entry. Competitors can design around excipient identity, concentration ranges, manufacturing steps, packaging, or dosage form while maintaining pharmaceutical equivalence.

When does hydroxyzine HCl lose exclusivity?

Hydroxyzine HCl has already lost practical market exclusivity. It is a mature generic drug, and commercial entry is generally available through ANDA-based competition where a qualifying reference product exists.

FDA exclusivity for a new hydroxyzine HCl product could arise only through a new regulatory strategy, such as:

• A qualified 505(b)(2) product with a novel dosage form or delivery system.
• Three-year exclusivity for an approved application containing new clinical investigations essential to approval.
• Orphan-drug exclusivity if the product qualifies for an orphan indication.
• Pediatric exclusivity attached to another qualifying exclusivity period.

These pathways would not restore exclusivity to ordinary hydroxyzine HCl tablets. They would protect only the qualifying product, indication, or application scope.

What is the Orange Book status of hydroxyzine HCl?

The Orange Book lists approved prescription drug products and relevant patent or exclusivity information by application. Hydroxyzine HCl products are generally represented by legacy NDA and generic ANDA products rather than an active innovative-product franchise.[3]

For commercial diligence, the relevant checks are:

1. Identify the reference listed drug for the proposed dosage form.
2. Review any listed patents under the specific NDA.
3. Check whether patents are active, expired, delisted, or subject to certification requirements.
4. Review therapeutic-equivalence codes for competing products.
5. Confirm whether the target product is a solution, tablet, capsule, or another dosage form.

A Paragraph IV challenge is unlikely to be commercially significant for ordinary hydroxyzine HCl tablets because the core molecule and conventional dosage forms are old. Paragraph IV risk becomes relevant if a sponsor develops a newly listed, patent-protected dosage form, taste-masking technology, oral film, device combination, or narrow method-of-use product.

Which companies are challenging hydroxyzine HCl patents?

No major branded patent challenge is central to the conventional hydroxyzine HCl market. Competition is primarily among generic manufacturers and contract manufacturers. Relevant commercial participants can include established generic companies, regional suppliers, hospital-focused manufacturers, and private-label distributors.

The market structure favors suppliers with:

• Reliable active pharmaceutical ingredient sourcing.
• Multiple qualified manufacturing sites.
• FDA-compliant oral-liquid capacity.
• Strong packaging and serialization capabilities.
• Low-cost tablet production.
• Established retail, institutional, and wholesaler contracts.

A new entrant is more likely to compete through product availability, packaging, shortage mitigation, or a differentiated dosage form than through patent litigation.

What FDA regulatory risks affect hydroxyzine HCl commercialization?

Hydroxyzine products carry clinically relevant sedation and cardiac safety considerations. The EMA’s Pharmacovigilance Risk Assessment Committee recommended restrictions on hydroxyzine use because of QT-interval prolongation and torsades de pointes risk, particularly in patients with risk factors or interacting medicines.[4]

Excipient strategy must therefore avoid creating unnecessary dosing variability or administration confusion. Key regulatory issues include:

• Concentration clarity in oral liquids.
• Accurate dosing devices.
• Child-resistant packaging.
• Preservative effectiveness.
• Extractables and leachables from liquid containers.
• Stability under labeled storage conditions.
• In-use stability after opening.
• Acceptable daily intake and labeling for excipients.
• Avoidance of excipients that create avoidable pediatric concerns.
• Consistent tablet strength and score performance.

The formulation should not encourage unapproved dose escalation or imply superior safety. Sedation, anticholinergic effects, and cardiac-risk labeling remain active product-management issues.

How strong is the patent estate for hydroxyzine HCl?

The patent estate is weak for the active ingredient and conventional products but can be moderate for a genuinely differentiated delivery system.

Product concept	Patent strength	Commercial defensibility
Standard immediate-release tablet	Low	Low
Conventional oral solution	Low	Low
Sugar-free oral solution	Low to moderate	Moderate if taste and stability are superior
Unit-dose oral syringe product	Moderate	Moderate, mainly through packaging and execution
Orally disintegrating tablet	Moderate	Moderate
Taste-masked oral film	Moderate to high	Potentially high if performance is difficult to replicate
Novel device combination	Moderate to high	Dependent on device claims and regulatory classification
New method of use	Variable	Dependent on clinical evidence and claim scope

Patent value rises when the formulation solves a documented problem and produces a measurable result. Taste masking, rapid disintegration, improved stability, and dose-error reduction are more defensible than routine substitution of one binder or sweetener for another.

What generic entry risks exist for new hydroxyzine HCl products?

Generic entry risk is high for standard tablets and conventional liquids. A new product should assume rapid substitution unless it has one or more of the following advantages:

• A differentiated dosage form.
• A protected formulation process.
• A strong institutional contract.
• A shortage-driven supply position.
• A clinically useful concentration or dosing device.
• Superior palatability supported by comparative testing.
• A low-cost manufacturing platform.
• A regulatory advantage in a specific market.

A 505(b)(2) product may obtain limited regulatory exclusivity, but the investment case depends on whether the dosage form supports a premium price. Hydroxyzine’s low-cost generic status places a ceiling on acceptable development and manufacturing expense.

How does hydroxyzine HCl compare with hydroxyzine pamoate?

Attribute	Hydroxyzine HCl	Hydroxyzine pamoate
Salt characteristics	More water-soluble	Less water-soluble
Common use in liquids	More suitable for solutions	More suitable for suspensions or capsules
Formulation priority	Taste, pH, preservation	Particle size, suspension stability, dissolution
Excipient burden	Sweeteners, flavors, buffers, preservatives	Suspending agents, wetting agents, taste masking
Pediatric liquid opportunity	Strong	More technically demanding
Patent opportunity	Dosage-form and taste masking	Particle engineering, suspension, and delivery systems

The hydrochloride salt is generally more attractive for clear oral liquids. The pamoate salt may offer different release and sensory characteristics but introduces greater suspension and particle-control requirements.

What licensing and partnership opportunities exist?

Licensing potential is limited for ordinary hydroxyzine HCl. More credible opportunities include:

• Licensing a taste-masking technology.
• Acquiring an oral-film platform.
• Partnering with a specialty liquid manufacturer.
• Contracting pediatric-focused packaging and dosing-device capabilities.
• Supplying private-label unit-dose products to long-term-care distributors.
• Licensing a stabilized preservative-free presentation.
• Developing regional products where access or supply reliability is poor.

The most viable transaction structure is likely a formulation or manufacturing partnership rather than a molecule license. Value should be tied to regulatory readiness, manufacturing reproducibility, and customer access.

Key Takeaways

• Hydroxyzine HCl is a mature generic with no meaningful remaining compound exclusivity.
• Conventional tablets and oral solutions have weak patent protection and high generic-entry risk.
• The best excipient opportunity is a palatable, stable, accurately dosed oral liquid.
• Pediatric, geriatric, sugar-free, dye-free, unit-dose, and oral-disintegrating products offer the clearest differentiation.
• Taste masking, preservative control, concentration selection, and packaging compatibility are the central technical issues.
• A new patent estate can be built around measurable formulation or delivery performance, not routine excipient substitution.
• Hydroxyzine’s sedation and QT-prolongation risks make dosing accuracy and regulatory labeling commercially important.
• Licensing value is more likely to reside in formulation technology, packaging, or manufacturing capacity than in the active ingredient.

FAQs

Can hydroxyzine HCl be formulated as a preservative-free oral solution?

Yes. A preservative-free product is most practical in unit-dose packaging or a validated multidose system with appropriate microbial controls. The commercial tradeoff is higher packaging and manufacturing cost.

Is hydroxyzine HCl suitable for an orally disintegrating tablet?

Yes. Its dose strength and solubility profile are compatible with an orally disintegrating tablet, but bitterness, moisture sensitivity, friability, and blister-packaging requirements must be controlled.

Which excipient creates the largest hydroxyzine HCl formulation risk?

The highest risk usually comes from the combined taste-masking and liquid-preservation system. An excipient can improve palatability while affecting pH, stability, viscosity, microbial control, or dosing accuracy.

Can a hydroxyzine HCl formulation receive new patent protection?

Yes, if the formulation contains a novel and non-obvious technical solution with measurable benefits. Routine tablets, standard sweetener systems, and ordinary excipient substitutions are unlikely to support strong claims.

Is hydroxyzine HCl a good candidate for a 505(b)(2) product?

It can be, particularly for an oral film, orally disintegrating tablet, novel concentration, or device-enabled presentation. The business case is constrained by low generic pricing and the need to demonstrate a commercially meaningful administration benefit.

References

1. U.S. Food and Drug Administration. (n.d.). Hydroxyzine hydrochloride prescribing information. FDA.
2. DailyMed. (n.d.). Hydroxyzine hydrochloride tablet and oral solution labeling. National Library of Medicine.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
4. European Medicines Agency. (2015). Hydroxyzine-containing medicinal products: Referral assessment report. EMA.
5. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.